(Q28287576)

2

0 references

Seyed-Mohammad-Reza Hosseini

3

0 references

Amirhossein Modabbernia

4

0 references

Mohammad-Reza Khodaie-Ardakani

5

0 references

Omid Mirshafiee

6

0 references

Mehdi Farokhnia

7

0 references

Masih Tajdini

8

0 references

Farzin Rezaei

9

0 references

Bahman Salehi

10

0 references

Mandana Ashrafi

11

0 references

Habibeh Yekehtaz

12

0 references

Mina Tabrizi

13

0 references

Shahin Akhondzadeh

https://scigraph.springernature.com/pub.10.1007/s00213-013-3064-2

14

0 references

language of work or name

English

0 references

publication date

August 2013

0 references

published in

Psychopharmacology

0 references

volume

228

0 references

issue

4

0 references

page(s)

595-602

0 references

exact match

0 references

cites work

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

The role of ondansetron in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Persistent negative symptoms in schizophrenia: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

The NIMH-MATRICS consensus statement on negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Tropisetron improves deficits in auditory P50 suppression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

The effect of Ondansetron on memory in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3064-2

Inhibition of NMDA-receptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: intracellular studies.

21 January 2018

1 reference

12 December 2020

Augmentation of clozapine therapy with ondansetron

1 reference

12 December 2020

Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

Role of serotonin in the action of atypical antipsychotic drugs

1 reference

12 December 2020

Ondansetron in treatment of schizophrenia

1 reference

12 December 2020

The 5-HT hypothesis of schizophrenia.

1 reference

12 December 2020

Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses

1 reference

12 December 2020

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

1 reference

12 December 2020

Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia.

1 reference

12 December 2020

A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia

1 reference

12 December 2020

10.1007/S00213-013-3064-2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2402024

Dimensions Publication ID

1014377136

0 references

OpenCitations bibliographic resource ID

2402024

1 reference